We are analyzing https://link.springer.com/article/10.1007/s00280-006-0287-5.

Title:
Poly(ethylene oxide)-modified poly(beta-amino ester) nanoparticles as a pH-sensitive system for tumor-targeted delivery of hydrophobic drugs: part 3. Therapeutic efficacy and safety studies in ovarian cancer xenograft model | Cancer Chemotherapy and Pharmacology
Description:
The objective of this study was to evaluate the anti-tumor efficacy and lack of systemic toxicity of paclitaxel when administered in pH-sensitive poly(ethylene oxide) (PEO)-modified poly(beta-amino ester) (PbAE) nanoparticles in mice bearing human ovarian adenocarcinoma (SKOV-3) xenograft. Paclitaxel-encapsulated PEO-modified PbAE (PEO–PbAE) nanoparticles were prepared by the solvent displacement method. PEO-modified poly(epsilon-caprolactone) (PCL) (PEO–PCL) nanoparticles were used as a non pH-responsive control formulation. Efficacy studies were conducted in SKOV-3 tumor-bearing athymic (Nu/Nu) mice at an equivalent paclitaxel dose of 20 mg/kg with the control and nanoparticle formulations. Safety of the drug when administered in the control and nanoparticle formulation was determined from blood cell counts and changes in body weight of the animals. The formulated paclitaxel-containing PEO–PbAE and PEO–PCL nanoparticles had a particle size in the range of 100–200 nm and a surface charge of + 39.0 and − 30.8 mV, respectively. After intravenous administration of paclitaxel in these formulations, the tumor growth was inhibited significantly. Both of the formulated nanoparticles tested have shown improved therapeutic efficacy as compared to the paclitaxel aqueous solution. Additionally, significantly lower toxicity profile of paclitaxel was observed with PEO-modified nanoparticles as compared to the aqueous solution formulation PEO-modified PbAE nanoparticles are a unique pH-sensitive drug delivery system that elicits enhanced efficacy and safety profile in solid tumor therapy.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Health & Fitness
Science

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We find it hard to spot revenue streams.

Earning money isn't the goal of every website; some are designed to offer support or promote social causes. People have different reasons for creating websites. This might be one such reason. Link.springer.com could be secretly minting cash, but we can't detect the process.

Keywords {🔍}

article, google, scholar, cas, pubmed, nanoparticles, cancer, delivery, res, tumor, langer, amiji, drug, polybetaamino, efficacy, polyethylene, ester, phsensitive, therapeutic, xenograft, pharm, system, shenoy, paclitaxel, human, polyepsiloncaprolactone, biodegradable, usa, privacy, cookies, content, oxidemodified, tumortargeted, safety, peomodified, control, size, access, vascular, jain, vivo, publish, search, hydrophobic, drugs, part, studies, ovarian, mice, phresponsive,

Topics {✒️}

2-deoxy-2-fluoro-beta-d-arabinofuranosyl peo/ppo/peo triblock copolymers month download article/chapter ph-responsive control formulation ph-responsive behavior improved albumin-binding doxorubicin prodrug ph-sensitive biodegradable system low-dose metronomic combined intermittent bolus-dose cyclophosphamide skov-3 tumor-bearing athymic high-resolution measurements reveal article cancer chemotherapy peo/ppo block copolymers paclitaxel aqueous solution human rhabdomyosarcoma xenografts american chemical society full article pdf related subjects ph-sensitive system privacy choices/manage cookies poly-epsilon-caprolactone microspheres drug delivery systems human tumor xenograft professor robert campbell tumor vascular permeability long-circulating small-scale systems pitt cg acid-cleavable bonds present address ph-sensitive poly dinesh shenoy block copolymer micelles drug-polymer conjugates implantable therapeutic systems zeta potential measurements tumor-targeted delivery blood cell counts tumor growth equivalent paclitaxel dose peo-modified nanoparticles beta-amino ester beta-amino esters colloidal drug carriers anti-tumor efficacy european economic area solvent displacement method β-amino esters article devalapally peo-modified poly

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Poly(ethylene oxide)-modified poly(beta-amino ester) nanoparticles as a pH-sensitive system for tumor-targeted delivery of hydrophobic drugs: part 3. Therapeutic efficacy and safety studies in ovarian cancer xenograft model
         description:The objective of this study was to evaluate the anti-tumor efficacy and lack of systemic toxicity of paclitaxel when administered in pH-sensitive poly(ethylene oxide) (PEO)-modified poly(beta-amino ester) (PbAE) nanoparticles in mice bearing human ovarian adenocarcinoma (SKOV-3) xenograft. Paclitaxel-encapsulated PEO-modified PbAE (PEO–PbAE) nanoparticles were prepared by the solvent displacement method. PEO-modified poly(epsilon-caprolactone) (PCL) (PEO–PCL) nanoparticles were used as a non pH-responsive control formulation. Efficacy studies were conducted in SKOV-3 tumor-bearing athymic (Nu/Nu) mice at an equivalent paclitaxel dose of 20 mg/kg with the control and nanoparticle formulations. Safety of the drug when administered in the control and nanoparticle formulation was determined from blood cell counts and changes in body weight of the animals. The formulated paclitaxel-containing PEO–PbAE and PEO–PCL nanoparticles had a particle size in the range of 100–200 nm and a surface charge of + 39.0 and − 30.8 mV, respectively. After intravenous administration of paclitaxel in these formulations, the tumor growth was inhibited significantly. Both of the formulated nanoparticles tested have shown improved therapeutic efficacy as compared to the paclitaxel aqueous solution. Additionally, significantly lower toxicity profile of paclitaxel was observed with PEO-modified nanoparticles as compared to the aqueous solution formulation PEO-modified PbAE nanoparticles are a unique pH-sensitive drug delivery system that elicits enhanced efficacy and safety profile in solid tumor therapy.
         datePublished:2006-07-22T00:00:00Z
         dateModified:2006-07-22T00:00:00Z
         pageStart:477
         pageEnd:484
         sameAs:https://doi.org/10.1007/s00280-006-0287-5
         keywords:
            Biodegradable
            pH sensitive
            Nanoparticles
            Poly(beta-amino ester)
            Poly(epsilon-caprolactone)
            Tumor targeting
            Efficacy
            Safety
            Oncology
            Pharmacology/Toxicology
            Cancer Research
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00280-006-0287-5/MediaObjects/280_2006_287_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00280-006-0287-5/MediaObjects/280_2006_287_Fig2_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00280-006-0287-5/MediaObjects/280_2006_287_Fig3_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00280-006-0287-5/MediaObjects/280_2006_287_Fig4_HTML.gif
         isPartOf:
            name:Cancer Chemotherapy and Pharmacology
            issn:
               1432-0843
               0344-5704
            volumeNumber:59
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer-Verlag
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Harikrishna Devalapally
               affiliation:
                     name:Northeastern University
                     address:
                        name:Department of Pharmaceutical Sciences, School of Pharmacy, Northeastern University, Boston, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Dinesh Shenoy
               affiliation:
                     name:Northeastern University
                     address:
                        name:Department of Pharmaceutical Sciences, School of Pharmacy, Northeastern University, Boston, USA
                        type:PostalAddress
                     type:Organization
                     name:Novavax, Inc.
                     address:
                        name:Novavax, Inc., Malvern, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Steven Little
               affiliation:
                     name:Massachusetts Institute of Technology
                     address:
                        name:Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, USA
                        type:PostalAddress
                     type:Organization
                     name:University of Pittsburgh
                     address:
                        name:Department of Chemical Engineering, University of Pittsburgh, Pittsburgh, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Robert Langer
               affiliation:
                     name:Massachusetts Institute of Technology
                     address:
                        name:Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Mansoor Amiji
               affiliation:
                     name:Northeastern University
                     address:
                        name:Department of Pharmaceutical Sciences, School of Pharmacy, Northeastern University, Boston, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Poly(ethylene oxide)-modified poly(beta-amino ester) nanoparticles as a pH-sensitive system for tumor-targeted delivery of hydrophobic drugs: part 3. Therapeutic efficacy and safety studies in ovarian cancer xenograft model
      description:The objective of this study was to evaluate the anti-tumor efficacy and lack of systemic toxicity of paclitaxel when administered in pH-sensitive poly(ethylene oxide) (PEO)-modified poly(beta-amino ester) (PbAE) nanoparticles in mice bearing human ovarian adenocarcinoma (SKOV-3) xenograft. Paclitaxel-encapsulated PEO-modified PbAE (PEO–PbAE) nanoparticles were prepared by the solvent displacement method. PEO-modified poly(epsilon-caprolactone) (PCL) (PEO–PCL) nanoparticles were used as a non pH-responsive control formulation. Efficacy studies were conducted in SKOV-3 tumor-bearing athymic (Nu/Nu) mice at an equivalent paclitaxel dose of 20 mg/kg with the control and nanoparticle formulations. Safety of the drug when administered in the control and nanoparticle formulation was determined from blood cell counts and changes in body weight of the animals. The formulated paclitaxel-containing PEO–PbAE and PEO–PCL nanoparticles had a particle size in the range of 100–200 nm and a surface charge of + 39.0 and − 30.8 mV, respectively. After intravenous administration of paclitaxel in these formulations, the tumor growth was inhibited significantly. Both of the formulated nanoparticles tested have shown improved therapeutic efficacy as compared to the paclitaxel aqueous solution. Additionally, significantly lower toxicity profile of paclitaxel was observed with PEO-modified nanoparticles as compared to the aqueous solution formulation PEO-modified PbAE nanoparticles are a unique pH-sensitive drug delivery system that elicits enhanced efficacy and safety profile in solid tumor therapy.
      datePublished:2006-07-22T00:00:00Z
      dateModified:2006-07-22T00:00:00Z
      pageStart:477
      pageEnd:484
      sameAs:https://doi.org/10.1007/s00280-006-0287-5
      keywords:
         Biodegradable
         pH sensitive
         Nanoparticles
         Poly(beta-amino ester)
         Poly(epsilon-caprolactone)
         Tumor targeting
         Efficacy
         Safety
         Oncology
         Pharmacology/Toxicology
         Cancer Research
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00280-006-0287-5/MediaObjects/280_2006_287_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00280-006-0287-5/MediaObjects/280_2006_287_Fig2_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00280-006-0287-5/MediaObjects/280_2006_287_Fig3_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00280-006-0287-5/MediaObjects/280_2006_287_Fig4_HTML.gif
      isPartOf:
         name:Cancer Chemotherapy and Pharmacology
         issn:
            1432-0843
            0344-5704
         volumeNumber:59
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer-Verlag
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Harikrishna Devalapally
            affiliation:
                  name:Northeastern University
                  address:
                     name:Department of Pharmaceutical Sciences, School of Pharmacy, Northeastern University, Boston, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Dinesh Shenoy
            affiliation:
                  name:Northeastern University
                  address:
                     name:Department of Pharmaceutical Sciences, School of Pharmacy, Northeastern University, Boston, USA
                     type:PostalAddress
                  type:Organization
                  name:Novavax, Inc.
                  address:
                     name:Novavax, Inc., Malvern, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Steven Little
            affiliation:
                  name:Massachusetts Institute of Technology
                  address:
                     name:Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, USA
                     type:PostalAddress
                  type:Organization
                  name:University of Pittsburgh
                  address:
                     name:Department of Chemical Engineering, University of Pittsburgh, Pittsburgh, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Robert Langer
            affiliation:
                  name:Massachusetts Institute of Technology
                  address:
                     name:Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Mansoor Amiji
            affiliation:
                  name:Northeastern University
                  address:
                     name:Department of Pharmaceutical Sciences, School of Pharmacy, Northeastern University, Boston, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Cancer Chemotherapy and Pharmacology
      issn:
         1432-0843
         0344-5704
      volumeNumber:59
Organization:
      name:Springer-Verlag
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Northeastern University
      address:
         name:Department of Pharmaceutical Sciences, School of Pharmacy, Northeastern University, Boston, USA
         type:PostalAddress
      name:Northeastern University
      address:
         name:Department of Pharmaceutical Sciences, School of Pharmacy, Northeastern University, Boston, USA
         type:PostalAddress
      name:Novavax, Inc.
      address:
         name:Novavax, Inc., Malvern, USA
         type:PostalAddress
      name:Massachusetts Institute of Technology
      address:
         name:Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, USA
         type:PostalAddress
      name:University of Pittsburgh
      address:
         name:Department of Chemical Engineering, University of Pittsburgh, Pittsburgh, USA
         type:PostalAddress
      name:Massachusetts Institute of Technology
      address:
         name:Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, USA
         type:PostalAddress
      name:Northeastern University
      address:
         name:Department of Pharmaceutical Sciences, School of Pharmacy, Northeastern University, Boston, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Harikrishna Devalapally
      affiliation:
            name:Northeastern University
            address:
               name:Department of Pharmaceutical Sciences, School of Pharmacy, Northeastern University, Boston, USA
               type:PostalAddress
            type:Organization
      name:Dinesh Shenoy
      affiliation:
            name:Northeastern University
            address:
               name:Department of Pharmaceutical Sciences, School of Pharmacy, Northeastern University, Boston, USA
               type:PostalAddress
            type:Organization
            name:Novavax, Inc.
            address:
               name:Novavax, Inc., Malvern, USA
               type:PostalAddress
            type:Organization
      name:Steven Little
      affiliation:
            name:Massachusetts Institute of Technology
            address:
               name:Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, USA
               type:PostalAddress
            type:Organization
            name:University of Pittsburgh
            address:
               name:Department of Chemical Engineering, University of Pittsburgh, Pittsburgh, USA
               type:PostalAddress
            type:Organization
      name:Robert Langer
      affiliation:
            name:Massachusetts Institute of Technology
            address:
               name:Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, USA
               type:PostalAddress
            type:Organization
      name:Mansoor Amiji
      affiliation:
            name:Northeastern University
            address:
               name:Department of Pharmaceutical Sciences, School of Pharmacy, Northeastern University, Boston, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Department of Pharmaceutical Sciences, School of Pharmacy, Northeastern University, Boston, USA
      name:Department of Pharmaceutical Sciences, School of Pharmacy, Northeastern University, Boston, USA
      name:Novavax, Inc., Malvern, USA
      name:Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, USA
      name:Department of Chemical Engineering, University of Pittsburgh, Pittsburgh, USA
      name:Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, USA
      name:Department of Pharmaceutical Sciences, School of Pharmacy, Northeastern University, Boston, USA
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(126)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

3.96s.

LINK . SPRINGER . COM {}